a look at zuma-2 trial
Published 4 years ago • 62 plays • Length 2:56Download video MP4
Download video MP3
Similar videos
-
1:26
dr. miklos on the results of the zuma-2 trial in mcl
-
1:22
dr. zonder on the zuma-2 and zuma-5 trials in mcl and inhl
-
1:10
zuma-2 trial demonstrates similar outcomes for high- and low-risk mcl
-
1:22
zuma-2 trial demonstrates efficacy in mantle cell lymphoma
-
3:54
zuma-2: outcomes of r/r mcl patients who progressed within 24 months of diagnosis
-
1:19
dr. wang discusses the zuma-2 trial in mantle cell lymphoma
-
16:40
mantle cell lymphoma: how to get into a clinical trial | bobby's story | the patient story
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
2:55
updates from zuma-7: axi-cel for r/r dlbcl
-
5:57
asco 2020: zuma-2 update
-
2:09
zuma series update: zuma-1 and zuma-2
-
4:59
zuma-7: axi-cel is superior to standard of care across common prognostic subgroups in r/r lbcl
-
0:46
key takeaway from 2-year follow-up data of zuma-1 trial in large b-cell lymphoma
-
2:56
implications of zuma-2 in r/r mantle cell lymphoma
-
1:59
michael wang, md, shares details from the zuma-2 trial in mantle cell lymphoma presented at ash 2019
-
6:45
anticipation of zuma-7 results
-
8:01
high-risk lymphoma: the zuma-1 and scholar-1 trials
-
1:11
dr. wang on comparative analysis of kte-x19 in higher- versus lower-risk r/r mcl
-
0:29
asco 2022: zuma-2, bcma-targeting bites & novel cars in myeloma
-
1:26
clinical trials look at promising treatments in mantle cell lymphoma
-
1:23
dr. locke on the zuma-i trial of kte-c19
-
1:09
dr. jacobson on the zuma-5 trial with axi-cel in high-risk relapsed/refractory inhl